ChatBlox™ further scales analytics in Value-Based Program Administration
ATLANTA, Nov. 4, 2025 /PRNewswire/ — HSBlox, a technology company empowering healthcare organizations with the tools and support to deliver value-based care (VBC) programs successfully and sustainably, today announced release 2.5 of its SmartBlox™ analytics solution.
With release 2.5, HSBlox has introduced a conversational AI module, ChatBlox™. The module enables capabilities for users to query their data in plain English using Large Language Models (LLM).
Highlights include:
“We are excited to offer our customers next-generation analytic capabilities within the context of the programs they operationalize and administer on our award-winning CureAlign® platform,” said HSBlox Chief Executive Officer Rahul Sharma. “Success within VBC programs requires a purpose-built infrastructure to address the needs of attributed populations at an individual patient level – improving patient health outcomes and containing costs.”
The CureAlign platform enables value-based program design, contract modeling and operational administration, including payment and reconciliation. With the HSBlox network-of-networks model for onboarding of complex participant relationships, administration of risk-bearing contracts and alternative payment models, VBC programs are simplified, accelerated and scalable.
About HSBlox
HSBlox empowers healthcare organizations with the tools and support to manage value-based programs successfully and sustainably. Our platform provides end-to-end administration, simplifies communication between stakeholders, and operationalizes complex contracts for the full range of reimbursement models. Wherever you are on your value-based journey, we’ll meet you there with smart, secure, scalable solutions. To learn more, browse our website and visit our LinkedIn page.
Media Contact:
Lynn Carroll
217-390-9450
lynn.carroll@hsblox.com
SOURCE HSBlox
ATLANTA, GA AND DOHA, QATAR / ACCESS Newswire / December 6, 2025 / Ameerex Corporation…
SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage…
– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial…
SPRING, Texas, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., a privately held pharmaceutical…
Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety…
TUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed…